Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 12.9.2016 | EN | Official Journal of the European Union | C 335/8 |

---

Judgment of the Court (First Chamber) of 7 July 2016 (request for a preliminary ruling from the Cour d’appel de Paris — France) — Genentech Inc. v Hoechst GmbH, Sanofi-Aventis Deutschland GmbH

(Case C-567/14)[(1)](#ntr1-C_2016335EN.01000801-E0001)

((Reference for a preliminary ruling - Competition - Article 101 TFEU - Non-exclusive licence agreement - Patent - No infringement - Obligation to pay royalties))

(2016/C 335/09)

Language of the case: French

Referring court

Cour d’appel de Paris

Parties to the main proceedings

Applicant: Genentech Inc.

Defendants: Hoechst GmbH, Sanofi-Aventis Deutschland GmbH

Operative part of the judgment

Article 101(1) TFEU must be interpreted as not precluding the imposition on the licensee, under a licence agreement such as that at issue in the main proceedings, of a requirement to pay a royalty for the use of a patented technology for the entire period in which that agreement was in effect, in the event of the revocation or non-infringement of a licensed patent, provided that the licensee was able freely to terminate that agreement by giving reasonable notice.

---

[Top](#document1)